Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Sep
Source: Bse
FMCG stocks · Micro cap · NSE
Manorama Industries Limited manufactures and supplies specialty fats and butters derived from exotic tree-borne oilseeds like Sal, Mango, Shea, and Kokum. It serves the food, confectionery, chocolate, and cosmetic sectors globally, operating on a 'Waste to Wealth' model with integrated processing capabilities and a focus on sustainable practices.
SMA20 -1.8% / mo · MACD − · sector -5.7pp vs Nifty 500 (3M)
Latest mapped FPI equity flow was not positive. View sector evidence
Adjusted completed-session prices, rebased to 100
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +39.3% · PAT +68.1% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Rev +39% YoY · PAT +68% YoY · operating leverage · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹404 Cr | +39.3% | +3.3% |
| EBITDA | ₹106 Cr | +41.3% | +9.3% |
| Operating margin | 26.0% | +0 bps | +100 bps |
| PAT | ₹79 Cr | +68.1% | +51.9% |
| PAT margin | 19.6% | +334 bps | +625 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 21/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Trend is weak — long-term uptrend intact. RSI 33.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
Consumer franchises can deserve higher multiples, but only when growth quality supports them.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in FMCG — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
FY26 Revenue grew 76.1% YoY to INR 13,577 Mn, with EBITDA up 92.5% YoY to INR 3,677 Mn, and PAT up 108.1% YoY to INR 2,332 Mn, driven by value-added offerings and capacity utilization. Q4FY26 saw revenue growth of 64.2% YoY, but PAT declined 12.8% QoQ due to MTM provisions.
Manorama delivered robust FY26 performance with significant revenue and profit growth, driven by increased capacity and value-added products. Strategic capex and backward integration in Africa aim to secure raw materials and expand specialty fat capacities. However, Q4FY26 saw a QoQ PAT decline due to MTM provisions on forward contracts, indicating FX volatility risk.
Latest issuer-disclosed distribution across 2 reported categories.
Planned strategic capex of approx. INR 460 crores over the next 2–3 years for forward and backward integration, including new manufacturing facilities and refinery expansion.
Deepening penetration to new geographies (MENA, Latin America) and tapping increased focus of the Food, Confectionery, Chocolate, and Cosmetic industries for CBEs and Exotic Specialty Fats & Butter.
R&D team's continuous quest to ideate, innovate, create, test, and launch alternative use cases of CBEs and Exotic Specialty Fats & Butter, aligning with market trends and customer requirements.
Economies of scale, operating leverage, backward integration, and seamless operations are expected to translate into operational efficiencies in the coming years.
Boosted installed capacity of SF2 by 30%, increasing it from 25,000 to 32,500 tonnes per annum through debottlenecking by end of FY26.
Plan to implement similar capacity enhancements for Solvent Fractionation Plant 1 (SF1), currently at 15,000 TPA.
Proposed capex includes a new manufacturing facility for Cocoa Butter Alternative (75,000 MTPA), a new Solvent Fractionation facility (75,000 MTPA), and a new refinery facility (90,000 MTPA) in India.
Proposed capex includes the establishment of a new processing plant in Burkina Faso (90,000 MTPA) for Shea Nuts and Mango Kernels.
Strong underlying industry demand for CBEs and exotic specialty fats, as they enhance product stability, improve melting characteristics, and extend shelf life in India’s tropical climatic conditions.
FSSAI allows 5% usage of CBE in chocolates from 1st January 2018, supporting product adoption.
Sustainable Waste-to-Wealth model and strong ESG practices contribute to a greener future and competitive advantage.
Adverse currency fluctuations resulted in a mark-to-market (MTM) provision of INR 17.05 crore in Q4FY26 and a cumulative INR 23.30 crore for FY26 on forward contracts.
The recognition of MTM provisions on forward contracts highlights the company's exposure to currency fluctuations and their potential impact on profitability.
Business relies on procuring exotic tree-borne seeds from scattered forest beds in India and West Africa, requiring a robust and efficient supply chain network.
The planned INR 460 crore capex over 2-3 years is subject to requisite statutory/regulatory approvals and successful implementation based on business requirements and market conditions.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Both YoY and QoQ comparisons are relevant. YoY highlights strong annual growth and market demand for specialty fats, while QoQ reveals sequential momentum and the impact of one-off items like MTM provisions on quarterly profitability.
Total Income grew by 76.1% YoY to INR 13,577 million in FY26, supported by a stronger product mix of value-added offerings and increased utilization of upgraded fractionation capacity.
Gross Profit margin for FY26 was 45.28% (FY25: 48.41%), a decline of 313 bps YoY. Q4FY26 Gross Profit margin was 43.9% (Q4FY25: 50.5%), a decline of 662 bps YoY.
EBITDA margin expanded by 230 bps YoY to 27.1% in FY26, driven by effective cost control measures and enhanced operational leverage. Q4FY26 EBITDA margin was 26.9% (Q4FY25: 27.4%), a decline of 54 bps YoY.
Working capital cycle improved to approximately 125 days in FY26 (FY25: 151 days).
Chairman and MD stated, 'Manorama Industries has once again delivered a sustainable performance during FY26.'
Management aims to 'further strengthening our leadership position through planned strategic capex of approx. INR 460 crores over the next 2–3 years.'
Management aims to 'diversify raw material sources, enhance global competitiveness and support long-term sustainable growth.'
Management remains 'dedicated and aim to strengthening every growth lever within our integrated value chain.'
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Revenue Growth | FY26: 76.1% YoY | Sustained growth momentum, especially from new capacities and product mix. |
| Gross Profit Margin | Q4FY26: 43.9% (down 662 bps YoY) | Stabilization or improvement in gross margins, indicating effective pricing and cost management. |
| Capex Execution | SF2 debottlenecking completed; INR 460 Cr capex planned over 2-3 years. | Progress on new manufacturing facilities in India and the processing plant in Burkina Faso. |
| Foreign Exchange Impact | Q4FY26 net foreign exchange loss of INR 7.58 crore due to MTM provisions. | Future impact of currency fluctuations and effectiveness of hedging policies. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 83rd percentile of the scored universe and 48th percentile within FMCG. Main check: cash conversion is weak at 53/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · FMCG: 48th pctile, median 79 · Micro: 70th pctile, median 73
59 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse